Amgen Inc., G. Kricorian Shareholder of: Amgen Inc., Employee of: Amgen Inc., W. Hua Employee of: Corrona, LLC, N. Accortt: None declared
DOI: 10.1136/annrheumdis-2018-eular.1509

FRI0113 SWITCHING TO ANTI-IL-6 BIOLOGICS AFTER ANTI-TNF THERAPY IN CHILDREN WITH JIA

E. Alexeeva^{1,2}, T. Dvoryakovskaya^{1,2}, M. Soloshenko¹, R. Denisova¹, K. Isaeva¹, A. Mamutova¹, V. Gladikh^{3,4}, A. Moskalev^{3,4}. ¹National Medical Research Center for Children's Health; ²Sechenov First Moscow State Medical University (Sechenov University), Moscow; ³EOL Labs Ltd, Department of Biostatistics; ⁴Institute of Computational Mathematics and Mathematical Geophysics SB RAS, Novosibirsk, Russian Federation

Background: Development of biologics gives rise to novel classes of drugs, offering more options for treating children with primary or secondary failure of anti-TNF therapy. However, the question of whether or not previous exposure to biologic therapy and the number of previously administered biologics influence the efficacy of current treatment still needs to be solved.

Objectives: To compare tocilizumab efficacy in biologics-naïve and biologics-switched patients with JIA.

Methods: Comparative analysis involved patients who had initiated TOC treatment at the National Medical Research Centre of Children's Health (Moscow) depending on previous history of biologics therapy. Treatment efficacy was evaluated according to the dynamics of clinical and laboratory signs using the ACR-Pedi criteria. The Wallace criteria were used to evaluate whether or not remission had been achieved.

Results: Thirty-two patients were biologics-naïve and 43 patients switched to TOC were previously treated with ETA (n=10), ADA (n=34), certolizumab (n=2), and infliximab (n=1). Children in the biologics-naïve group differed from the switchers in a number of important baseline parameters: shorter disease duration (2.13 [1.25-5.34] and 7.42 [3.10-7.5] years, respectively; p<0.001) and lower arthritis severity indices (the number of joints affected, the CHAQ and JADAS scores). Therapy with TOC in children was found very effective. The CHAQ and JADAS disease activity scores, the CRP and ESR laboratory values, morning stiffness duration, and the VAS score (assessed by both patient and physician), and the number of affected joints (swollen or painful joints, joints with the limited range of motion and with active arthritis) significantly decreased after 4 week therapy in all patients (p<0.01). The percentages of biologics-naïve patients and switchers who achieved ACR90 after the first 12 months of therapy were 31.25% and 25.6%, respectively (p=0.613). A smaller percentage of children achieved stable remission: 4.65% of switchers and 6.25% of biologics-naïve patients (p>0.999).

Conclusions: Tocilizumab therapy is highly efficient both as the first and subsequent biologic agent. Children with history of therapy with at least one biologic agent have lower chances for achieving remission during the first 12 months of therapy. However, this difference is most likely caused by the longer and more severe arthritis course in children allocated to the group of biologics-switched patients compared to biologics-naïve ones. Further matched large-cohort study is needed to identify predictors of response to therapy.

Disclosure of Interest: E. Alexeeva: None declared, T. Dvoryakovskaya Grant/research support from: Roche, Pfizer, M. Soloshenko: None declared, R. Denisova: None declared, K. Isaeva: None declared, A. Mamutova: None declared, V. Gladikh: None declared, A. Moskalev: None declared
DOI: 10.1136/annrheumdis-2018-eular.6526

FRI0114 EFFICACY AND RETENTION RATE OF CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS: DATA FROM A LARGE REAL-LIFE MULTICENTRE RETROSPECTIVE COHORT

E.G. Favalli¹, A. Becciolini¹, P. Sarzi Puttini², F. Atzeni³, R. Bortolotti⁴, S. Monti⁵, C. Lomater⁶, R. Gorla⁷, C. Bazzani⁷, R. Caporali⁵, on behalf of on behalf of LORHEN group. ¹Department of Rheumatology, Gaetano Pini Institute; ²Rheumatology Unit, University Hospital L. Sacco, Milano; ³Rheumatology, University of Messina, Messina; ⁴Rheumatology Unit, Santa Chiara Hospital, Trento; ⁵Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia; ⁶Rheumatology, Ospedale Mauriziano, Torino; ⁷Rheumatology Unit, Spedali Civili, Brescia, Italy

Background: Even though certolizumab pegol (CZP) has been licensed for the treatment of rheumatoid arthritis (RA) since longtime, observational data in a real-life setting are still lacking.

Objectives: To retrospectively evaluate the use of CZP in a multicentric observational cohort of Northern Italy (the LORHEN registry), calculating both clinical response and retention rate. To explore the effectiveness of CZP in childbearing age female.

Methods: Data were retrospectively extracted from the LORHEN registry which includes all RA patients treated with CZP as first or second-line biologic agent between December 2010 and April 2017. The 2 year clinical response was evaluated as EULAR response and proportion of patients achieving Disease Activity Score 28 (DAS28-ESR) remission. The 5 year retention rate was calculated by Kaplan-Meier method. Cox proportional hazard models were developed to examine potential predictors of CZP persistence, including sex, line of CZP treatment (naïve vs switchers), childbearing age, and concomitant MTX as categorical variables, whereas age, disease duration, and baseline DAS28-ESR as continuous variables.

Results: The overall study population included 242 RA patients (78.9% female; mean $\pm$ standard deviation, SD] age 54.2 $\pm$ 13.8 years; mean disease duration 10 $\pm$ 13.1 years; baseline DAS28-ESR 4.58 $\pm$ 1.39), who received CZP as first- (64%) or second-line (36%) biologic agent, as monotherapy (40.9%) or in combination with methotrexate (MTX, 59.1%). Two-year EULAR good +moderate response and remission rates were similar in first- and second-line patients (66% vs 60.7% [p=0.65] and 39.6% vs 32.1% [p=0.52], respectively). The overall 5 year retention rate was 42.5%, with no difference between first- and second-line therapy (43.5% vs 40.5%, respectively; p=0.98), but with a clear trend in favour of childbearing subpopulation versus older women (62.8% vs 32.3%, respectively; p=0.07). Concomitant MTX was a predictor of CZP persistence (Hazard Ratio [HR] 1.79, 95% confidence interval [95% CI] 1.08–2.95; p=0.02), whereas sex (HR 1.35, 95% CI 0.71–2.54, p=0.35), age (HR 1.01, 95% CI 0.99–1.03; p=0.14), mean disease duration (HR 0.99, 95% CI 0.97–1.02; p=0.87), and baseline DAS28-ESR (HR 1.15, 95% CI 0.96–1.38; p=0.12) were not associated with CZP retention rate. The most frequent reason for discontinuation was inefficacy (60%), whereas only 21% of patients stopped the drug because of adverse events.

Conclusions: In our real-life experience, CZP showed a very good clinical response, with more than one third of patients achieving 2 year clinical remission and more than 40% persisting on treatment after 5 years. Unexpectedly, no significant difference was found between first and second line of treatment. The use of CZP in childbearing women seems to be associated with a higher retention rate.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4160

FRI0115 INDIRECT STANDARDISED ASSESSMENT OF INJECTION SITE PAIN FOLLOWING SUBCUTANEOUS ADMINISTRATION OF CITRATE-FREE FORMULATION OF ADALIMUMAB AND ITS BIOSIMILAR ABP 501

E. Krishnan, N. Zhang, H. Wang, R. Kaushik. Biosimilars Development, Amgen Inc., Thousand Oaks, USA

Background: In randomised double-blind studies in patients with rheumatoid arthritis (RA) and psoriasis (PsO), ABP 501, an approved adalimumab biosimilar, had significantly lower injection site pain (ISP) perception compared with the citrate-containing formulation (CCF) of adalimumab reference product (RP) (40 mg/0.8 mL); however, there have been no direct or indirect comparisons of ISP perception between ABP 501 and the CCF of the RP (40 mg/0.4 mL).

Objectives: To demonstrate that pain perception after injection of both the ABP 501 formulation and the CFF-RP formulation was lower than after CCF-RP.

Methods: We analysed ISP perception data after injection from two ABP 501 phase 3 studies, one in patients with RA (NCT01970475) and another in patients with PsO (NCT01970488) and 2 citrate-free RP formulation studies (NCT01561313, NCT01502423) where the "control" group received the CCF-RP. In all studies, patients were equally randomised between the 2 treatment arms. Patients were asked to rate the ISP perception on a visual analogue scale (VAS) on which the current pain level was marked from 0 cm (no pain) to 10 cm (worst possible pain). We calculated Cohen's d-statistic for difference in ISP perception with ABP 501 compared with CCF-RP for the 2 ABP 501 studies. Similar comparisons were performed between the ISP perception associated with CFF-RF and CCF-RF. These measures were subsequently compared in a descriptive manner.

Results: Both ABP 501 and CFF-RF were associated with lower ISP perception after injection with maximum reduction observed immediately post-injection. The 95% confidence intervals of relative reduction in ISP perception for ABP 501 formulation and the CFF-RP (table 1) were provided descriptively.

Abstract FRI0115 – Table 1. Cross-sectional indirect comparison of ISP after injection between adalimumab CFF and ABP 501.

Time point of pain assessment	Within 2 minutes		Within 5 minutes		15 minutes after injection	
Investigational products	CFF-RP vs. CCF-RP		ABP 501 vs. CCF-RP		CFF-RP vs. CCF-RP	
Study	Study 1	Study 2	RA study baseline visit	PsO study baseline visit	Study 1	Study 2
Overall number of subjects	62	60	526	343	62	60
Mean (SD) [n] ISP VAS score for CCF-RP (cm)	3.3 (2.2) [62]	4.2 (2.8) [60]	2.1 (2.3) [262]	1.9 (2.0) [173]	1.0 (1.52) [62]	1.0 (1.61) [60]
Mean (SD) [n] ISP VAS score for ABP 501/CCF-RP (cm)	1.6 (2.1) [62]	0.9 (1.1) [60]	1.0 (1.6) [264]	0.5 (0.8) [170]	0.9 (1.66) [62]	0.4 (1.08) [60]
Difference in mean VAS score (cm)	1.7	3.3	1.1	1.4	0.1	0.6
Cohen's d statistic (95% confidence interval)	0.80 (0.42, 1.19)	1.56 (1.19, 1.94)	0.56 (0.39, 0.73)	0.92 (0.76, 1.08)	0.06 (-0.22, 0.34)	0.44 (0.20, 0.69)

Conclusions: Compared with CCF-RP, both ABP 501 and CFF-RP were associated with lower injection site pain perception.

REFERENCE:

[1] Nash P, et al. *Rheumatol Ther* 2016;3(2):257–270.

Disclosure of Interest: E. Krishnan Shareholder of: Amgen Inc., Employee of: Amgen Inc., N. Zhang Shareholder of: Amgen Inc., Employee of: Amgen Inc., H. Wang Shareholder of: Amgen Inc., Employee of: Amgen Inc., R. Kaushik Shareholder of: Amgen Inc., Employee of: Amgen Inc.

DOI: 10.1136/annrheumdis-2018-eular.6595

FRI0116

IMPACT OF PRIOR BIOLOGIC USE ON TREATMENT RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB IN ROUTINE CLINICAL CARE: RESULTS FROM THE PASSION STUDY

F. Van den Bosch¹, S. Wassenberg², P. Zueger³, J. Kalabic⁴, M. Wu³, K. Monastiriakos³, A. Ostor⁵. ¹Ghent University Hospital, Ghent, Belgium; ²Rheumazentrum Ratingen, Ratingen, Germany; ³AbbVie, N Chicago, USA; ⁴AbbVie Deutschland Co. GmbH, Ludwigshafen, Germany; ⁵Cabrini Medical Centre, Melbourne, Australia

Background: It is recognised that early diagnosis and treatment are important in maximising long-term quality of life in patients (pts) with rheumatoid arthritis (RA). Prior biologic disease modifying antirheumatic drug (bDMARD) use has been shown to affect treatment response to further biologic therapy including adalimumab (ADA).

Objectives: To evaluate the impact of prior bDMARD use on clinical and pt-reported outcomes in pts enrolled in the PASSION study.

Methods: PASSION was a 78-wk postmarketing, multinational, observational study that assessed the effectiveness of ADA in pts with moderate to severe RA receiving ADA in routine clinical care in the context of participation in the voluntary AbbVie pt support program. Pts with an insufficient response to ≥ 1 DMARD (1 prior bDMARD was allowed) and newly initiating ADA were enrolled and categorised as bDMARD-naïve or bDMARD-experienced. For the present analysis, ADA treatment response was determined by evaluating least squares (LS) mean change from baseline for multiple clinical and pt-reported outcomes (table 1). Missing data for each efficacy endpoint were imputed using last observation carried forward, and differences between groups for efficacy endpoints at wks 24, 52, and 78 were based on ANCOVA models adjusting for baseline and demographic variables (table 1). Additionally, the percentages of pts at each time point (observed population) who achieved HAQ-DI minimal clinically important difference (MCID; improvement from baseline of ≥ 0.22) were assessed.

Results: Of 1025 pts included in the intent-to-treat population, 182 were bDMARD-experienced and 843 were bDMARD-naïve at baseline. There were no significant differences between groups in sex, race, ethnicity, weight, height, body mass index, TJC28, SJC28, and pain at baseline. However, bDMARD-

experienced pts were significantly older, had longer RA duration, and had lower values for HAQ-DI, DAS28(CRP), CDAI, SDAI, PtGA, and PhGA than bDMARD-naïve pts at baseline ($p < 0.05$ for all). ADA treatment response was significantly higher for bDMARD-naïve vs bDMARD-experienced pts at all timepoints for HAQ-DI, DAS28(CRP), CDAI, PtGA, and pain, at wks 24 and 52 for SDAI, and at wk 24 for TJC28 and SJC28 (table 1). In the observed population, a large percentage of bDMARD-naïve and bDMARD-experienced pts achieved HAQ-DI MCID at wk 24 (67% and 60%), wk 52 (71% and 65%), and wk 78 (74% and 59%).

Abstract FRI0116 – Table 1. Least Squares Mean Change from Baseline in Efficacy Measures by Prior bDMARD Use at Each Study Visit (Intent-to-Treat Population, LOCF)

Measure	Visit	bDMARD-Naïve		bDMARD-Experienced		Naïve vs Experienced
		N	LS Mean Change (SE)	N	LS Mean Change (SE)	
TJC28	Week 24	787	-6.05 (1.064)	164	-4.87 (1.136)	0.015*
	Week 52	795	-4.75 (1.122)	166	-3.99 (1.198)	0.139
	Week 78	797	-7.02 (1.190)	167	-6.03 (1.271)	0.066
SJC28	Week 24	787	-4.75 (0.750)	165	-3.96 (0.800)	0.019*
	Week 52	795	-4.23 (0.781)	167	-3.65 (0.833)	0.099
	Week 78	797	-5.87 (0.846)	168	-5.28 (0.903)	0.124
HAQ-DI	Week 24	799	-0.44 (0.107)	168	-0.29 (0.114)	0.001**
	Week 52	807	-0.52 (0.116)	171	-0.31 (0.124)	<0.001***
	Week 78	808	-0.49 (0.120)	171	-0.31 (0.128)	<0.001***
DAS28(CRP)	Week 24	721	-1.83 (0.263)	148	-1.34 (0.283)	<0.001***
	Week 52	748	-1.62 (0.275)	154	-1.27 (0.296)	0.007**
	Week 78	755	-2.05 (0.288)	154	-1.67 (0.310)	0.005**
CDAI	Week 24	743	-16.77 (2.299)	159	-13.65 (2.458)	0.003**
	Week 52	753	-14.48 (2.401)	161	-12.10 (2.568)	0.030*
	Week 78	756	-20.14 (2.570)	161	-17.18 (2.749)	0.011*
SDAI	Week 24	703	-18.27 (2.539)	147	-14.45 (2.731)	0.001**
	Week 52	729	-16.16 (2.613)	152	-13.42 (2.807)	0.025*
	Week 78	734	-21.59 (2.756)	152	-19.09 (2.960)	0.052
Pt Pain	Week 24	799	-22.21 (4.940)	168	-17.04 (5.283)	0.019*
	Week 52	806	-19.50 (5.124)	171	-14.27 (5.473)	0.022*
	Week 78	807	-32.40 (5.281)	171	-26.87 (5.642)	0.019*
PtGA	Week 24	799	-21.22 (4.819)	168	-13.31 (5.159)	<0.001***
	Week 52	807	-20.34 (4.998)	171	-14.01 (5.346)	0.005**
	Week 78	808	-28.60 (5.132)	171	-21.60 (5.490)	0.002**
PhGA	Week 24	763	-30.49 (4.482)	161	-27.25 (4.824)	0.118
	Week 52	771	-28.40 (4.616)	162	-26.00 (4.966)	0.260
	Week 78	774	-34.24 (4.855)	163	-30.24 (5.223)	0.074

***, **, * statistically significant at $P < 0.001$, 0.01, and 0.05 levels, respectively for LS mean difference. Missing data were imputed for each efficacy endpoint using LOCF. The differences between two groups in efficacy endpoints at week 24, 52 and 78 were based on ANCOVA models adjusting for baseline and demographic variables (sex, race, ethnicity, age [years], PSP participation [ever (PSP users) vs never (PSP non-users)], diagnosis RA duration [years]).

ANCOVA, analysis of covariance; bDMARD, biologic disease modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; DAS28(CRP), 28-joint Disease Activity Score C-Reactive Protein; HAQ-DI, Health Assessment Questionnaire Disability Index; LOCF, last observation carried forward; PhGA, physician global assessment of disease activity; PSP, Patient Support Program; PtGA, patient global assessment of disease activity; SDAI, Simplified Disease Activity Index; SJC28, Swollen 28-Joint Count; TJC28, Tender-28-Joint Count.

Conclusions: Among pts with moderate to severe RA that initiated ADA treatment in the PASSION study, bDMARD-naïve pts achieved significantly larger improvements from baseline to wk 78 in a variety of clinical and pt-reported outcomes compared with bDMARD-experienced pts. A large proportion of both bDMARD-naïve and bDMARD-experienced pts achieved HAQ-DI MCID with ADA treatment.

Acknowledgements: AbbVie funded the study and analysis, and approved the abstract for submission. Medical writing support was provided by Wendy van der Spuy, PhD, of Complete Healthcare Communications, LLC (West Chester, PA, USA), and was funded by AbbVie.

Disclosure of Interest: F. Van den Bosch Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB, Consultant for: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB, S. Wassenberg Grant/research support from: AbbVie, BMS, Fuji, Gilead, Novartis, Pfizer, Roche, Sandoz, and UCB, Consultant for: AbbVie, Celgene, Janssen, Chugai, Lilly, Novartis, Pfizer, MSD, and UCB, Speakers bureau: AbbVie, Celgene, Janssen, Chugai, Lilly, Novartis, Pfizer, MSD, and UCB, P. Zueger Employee of: AbbVie, J. Kalabic Employee of: AbbVie, M. Wu Employee of: AbbVie, K. Monastiriakos Employee of: AbbVie, A. Ostor Grant/research support from: Lilly, Roche, MSD, AbbVie, Pfizer, Novartis, Janssen, and Bristol-Myers Squibb, Consultant for: Lilly, Roche, MSD, AbbVie, Pfizer, Novartis, Janssen, and Bristol-Myers Squibb

DOI: 10.1136/annrheumdis-2018-eular.6934